Literature DB >> 12658365

Pramipexole in comparison to l-dopa: a neuropsychological study.

L Brusa1, A Bassi, A Stefani, M Pierantozzi, A Peppe, M D Caramia, L Boffa, S Ruggieri, P Stanzione.   

Abstract

Twenty right-handed patients affected by early/mild Parkinson's disease were evaluated in a randomised study using neuropsychological and clinical assessements during three treatment modalities: when in the off treatment condition, when on pramipexole, and when on l-dopa. In comparison to the off treatment condition, the DA-agonist pramipexole produced a significant impairment of short term verbal memory, attentional-executive functions and verbal fluency, while l-dopa did not. Moreover, pramipexole opposite to l-dopa, failed to improve FAS and Stroop tests. Present findings indicate that pramipexole may worsen cognitive functions although not exceeding normative values.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12658365     DOI: 10.1007/s00702-002-0811-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  22 in total

Review 1.  CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.

Authors:  Alessandro Stefani; Livia Brusa; Enrica Olivola; Mariangela Pierantozzi; Alessandro Martorana
Journal:  J Neural Transm (Vienna)       Date:  2012-05-24       Impact factor: 3.575

Review 2.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

3.  Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?

Authors:  Rupam Borgohain; Rukmini Mridula Kandadai; Afshan Jabeen; Meena A Kannikannan
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

4.  Persistence of associations between cognitive impairment and motor dysfunction in the early phase of Parkinson's disease.

Authors:  Magdalena E Domellöf; Lars Forsgren; Eva Elgh
Journal:  J Neurol       Date:  2013-05-29       Impact factor: 4.849

Review 5.  The potential role of dopamine D₃ receptor neurotransmission in cognition.

Authors:  Shinichiro Nakajima; Philip Gerretsen; Hiroyoshi Takeuchi; Fernando Caravaggio; Tiffany Chow; Bernard Le Foll; Benoit Mulsant; Bruce Pollock; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2013-06-20       Impact factor: 4.600

6.  Do patient's get angrier following STN, GPi, and thalamic deep brain stimulation.

Authors:  Adam P Burdick; Kelly D Foote; Samuel Wu; Dawn Bowers; Pam Zeilman; Charles E Jacobson; Herbert E Ward; Michael S Okun
Journal:  Neuroimage       Date:  2010-10-04       Impact factor: 6.556

7.  Dopamine and impulse control disorders in Parkinson's disease.

Authors:  Daniel Weintraub
Journal:  Ann Neurol       Date:  2008-12       Impact factor: 10.422

8.  The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients.

Authors:  Livia Brusa; Valentina Pavino; Maria Carla Massimetti; Raffaele Bove; Cesare Iani; Paolo Stanzione
Journal:  Funct Neurol       Date:  2013 Jan-Mar

Review 9.  Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review.

Authors:  Michele Poletti; Ubaldo Bonuccelli
Journal:  Ther Adv Psychopharmacol       Date:  2013-04

10.  Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

Authors:  Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R Williams
Journal:  Mov Disord       Date:  2009-01-30       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.